---
title: "Amphastar Pharmaceuticals (AMPH) Gets a Hold from Bank of America Securities"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/273080633.md"
description: "Bank of America Securities analyst Pavan Patel has maintained a Hold rating on Amphastar Pharmaceuticals (AMPH) with a price target of $30.00. Patel, a 2-star analyst, has an average return of 2.2% and a 60% success rate. The consensus among analysts for Amphastar Pharmaceuticals is a Moderate Buy, with an average price target of $30.60."
datetime: "2026-01-20T11:56:36.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/273080633.md)
  - [en](https://longbridge.com/en/news/273080633.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/273080633.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/273080633.md) | [繁體中文](https://longbridge.com/zh-HK/news/273080633.md)


# Amphastar Pharmaceuticals (AMPH) Gets a Hold from Bank of America Securities

In a report released today, Pavan Patel from Bank of America Securities maintained a Hold rating on Amphastar Pharmaceuticals, with a price target of $30.00.

### Claim 50% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

According to TipRanks, Patel is a 2-star analyst with an average return of 2.2% and a 60.00% success rate. Patel covers the Healthcare sector, focusing on stocks such as Supernus Pharmaceuticals, Catalyst Pharma, and Amphastar Pharmaceuticals.

Currently, the analyst consensus on Amphastar Pharmaceuticals is a Moderate Buy with an average price target of $30.60.

### Related Stocks

- [ARK Genomic Revolution ETF (ARKG.US)](https://longbridge.com/en/quote/ARKG.US.md)
- [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/en/quote/IBBQ.US.md)
- [ALPS Medical Breakthroughs ETF (SBIO.US)](https://longbridge.com/en/quote/SBIO.US.md)
- [State Street®HlthCrSelSectSPDR®ETF (XLV.US)](https://longbridge.com/en/quote/XLV.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/en/quote/BBH.US.md)
- [Amphastar Pharmaceuticals, Inc. (AMPH.US)](https://longbridge.com/en/quote/AMPH.US.md)
- [ProShares Ultra Nasdaq Biotechnology (BIB.US)](https://longbridge.com/en/quote/BIB.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/en/quote/IBB.US.md)
- [State Street® SPDR® S&P® Biotech ETF (XBI.US)](https://longbridge.com/en/quote/XBI.US.md)
- [iShares US Pharmaceuticals ETF (IHE.US)](https://longbridge.com/en/quote/IHE.US.md)
- [Vanguard Health Care ETF (VHT.US)](https://longbridge.com/en/quote/VHT.US.md)
- [First Trust NYSE Arca Biotech ETF (FBT.US)](https://longbridge.com/en/quote/FBT.US.md)
- [iShares Global Healthcare ETF (IXJ.US)](https://longbridge.com/en/quote/IXJ.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/en/quote/PBE.US.md)

## Related News & Research

- [Royce & Associates LP Raises Stock Holdings in Amphastar Pharmaceuticals, Inc. $AMPH](https://longbridge.com/en/news/277768061.md)
- [Insights Ahead: Amphastar Pharma's Quarterly Earnings](https://longbridge.com/en/news/276928559.md)
- [Amphastar Q4 revenue misses estimates](https://longbridge.com/en/news/277102773.md)
- [Glenmark Pharmaceuticals Gets US FDA Nod for Fluticasone Propionate Inhalation Aerosol](https://longbridge.com/en/news/277723441.md)
- [Xeris Biopharma Q4 product revenue beats analyst expectations, driven by higher patient demand](https://longbridge.com/en/news/277460502.md)